Plant Name: Hibiscus syriacus
Taxonomic Information:
Plant ID: NPO29062
Plant Latin Name: Hibiscus syriacus
Taxonomy Genus: Hibiscus
Taxonomy Family: Malvaceae
Plant External Links:
NCBI TaxonomyDB:
106335
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Thailand; South Korea; China; India; RussiaTraditional Medicine System:
Indian Folk; TCMMedicinal Functions:
Anthelmintic; Antiphlogistic; Antipruritic; Demulcent; Diuretic; Emollient; Expectorant; Febrifuge; Ophthalmic; Skin; Stomachic; Styptic
Geographical Distribution:
India; South Korea; China; Russia; Thailand
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR2B; | |
| TOP1; | |
| MTOR; SCD; | |
| CHEK1; | |
| CA9; | |
| NR1H4; | |
| NFKB1; HIF1A; TP53; | |
| PMP22; GMNN; HBB; THPO; LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Enzyme_unclassified | SCD | Acyl-CoA desaturase | O00767 | CHEMBL5555 |
| Isomerase | TOP1 | DNA topoisomerase I | P11387 | CHEMBL1781 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Protein Kinase | CHEK1 | Serine/threonine-protein kinase Chk1 | O14757 | CHEMBL4630 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | PMP22 | Peripheral myelin protein 22 | Q01453 | CHEMBL1293298 |
| Unclassified | GMNN | Geminin | O75496 | CHEMBL1293278 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0050896; response to stimulus | GO:0042493; response to drug | 1.592E-06 | 9.443E-03 | CA9, HBB, HTR2B, MTOR, NFKB1, TOP1, TP53 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.788E-06 | 9.443E-03 | HIF1A, LMNA, MTOR, TP53 |
| BP | GO:0009987; cellular process | GO:0043618; regulation of transcription from RNA polymerase II promoter in response to stress | 2.405E-06 | 9.443E-03 | CA9, CHEK1, HIF1A, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.363E-05 | 2.054E-03 | TP53, HIF1A, MTOR |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.537E-05 | 2.054E-03 | TP53, NFKB1, MTOR |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 6.518E-05 | 2.054E-03 | TP53, NFKB1, MTOR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 8.559E-05 | 2.054E-03 | HIF1A, NFKB1, MTOR |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.965E-04 | 4.066E-03 | HIF1A, TP53, NFKB1, MTOR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.282E-04 | 2.461E-03 | TP53, HIF1A, MTOR |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.124E-04 | 3.399E-03 | LMNA, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 6.308E-04 | 6.923E-03 | TP53, HIF1A, MTOR |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 6.490E-04 | 6.923E-03 | CHEK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.056E-03 | 9.524E-03 | NFKB1, MTOR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 1.262E-03 | 9.524E-03 | CHEK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.371E-03 | 9.524E-03 | TP53, MTOR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 1.169E-03 | 9.524E-03 | HIF1A, MTOR |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.413E-03 | 9.524E-03 | TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.725E-03 | 9.740E-03 | TP53, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 1.587E-03 | 9.524E-03 | NFKB1, MTOR |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04115 | p53 signaling pathway | 1.543E-03 | 9.524E-03 | CHEK1, TP53 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MTOR; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B; |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TOP1; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | TOP1; |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2B; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | TOP1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | TOP1; MTOR; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | TOP1; |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; SCD; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TOP1; TP53; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; HTR2B; |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2B; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | SCD; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR; |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | TOP1; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | TOP1; CHEK1; NFKB1; HIF1A; TP53; MTOR; CA9; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | TOP1; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| C00-D49: Neoplasms | Breast cancer | C50 | TOP1; CA9; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Advanced ovarian cancer | NA | TOP1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | SCD; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP1; CHEK1; HIF1A; TP53; MTOR; CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | CHEK1; MTOR; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | CHEK1; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | TOP1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MTOR; |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | SCD; |
| NA: NA | Coronary artery restenosis | NA | MTOR; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | MTOR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | TOP1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CHEK1; HIF1A; MTOR; CA9; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TOP1; TP53; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TOP1; |
| C00-D49: Neoplasms | Gastric cancer | C16 | TOP1; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | CHEK1; MTOR; |
| C00-D49: Neoplasms | Renal cancer | C64 | MTOR; CA9; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
